Abstract
Intraplaque haemorrhage (IPH) represents a critical feature of plaque vulnerability as it is robustly associated with adverse cardiovascular events, including stroke and myocardial infarction. How IPH drives plaque instability is unknown. However, its identification and quantification in atherosclerotic plaques is currently performed manually, with high inter- observer variability, limiting its accurate assessment in large cohorts. Leveraging the Athero- Express biobank, an ongoing study comprising a comprehensive dataset of histological, transcriptional, and clinical information from 2,595 carotid endarterectomy patients, we developed an attention-based additive multiple instance learning (MIL) framework to automate the detection and quantification of IPH across whole-slide images of nine distinct histological stains. We demonstrate that routinely available Haematoxylin and Eosin (H&E) staining outperformed all other plaque relevant Immunohistochemistry (IHC) stains tested (AUROC = 0.86), underscoring its utility in quantifying IPH. When combining stains through ensemble models, we see that H&E + CD68 (a macrophage marker) as well as H&E + Verhoeff-Van Gieson elastic fibers staining (EVG) leads to a substantial improvement (AUROC = 0.92). Using our model, we could derive IPH area from the MIL-derived patch-level attention scores, enabling not only classification but precise localisation and quantification of IPH area in each plaque, facilitating downstream analyses of its association and cellular composition with clinical outcomes. By doing so, we demonstrate that IPH presence and area are the most significant predictors of both preoperative symptom presentation and major adverse cardiovascular events (MACE), outperforming manual scoring methods. Automating IPH detection also allowed us to characterise IPH on a molecular level at scale. Pairing IPH measurements with single-cell transcriptomic analyses revealed key molecular pathways involved in IPH, including TNF-α signalling, extracellular matrix remodelling and the presence of foam cells. This study represents the largest effort in the cardiovascular field to integrate digital pathology, machine learning, and molecular data to predict and characterize IPH which leads to better understanding how it drives symptoms and MACE. Our model provides a scalable, interpretable, and reproducible method for plaque phenotyping, enabling the derivation of plaque phenotypes for predictive modelling of MACE outcomes.
Competing Interest Statement
Dr. Sander W. van der Laan and Prof. Dr. Gerard Pasterkamp received Roche funding for unrelated work. Dr. Craig A. Glastonbury is an advisor to Population Health Partners (PHP) and their portfolio companies. Dr. Clint L. Miller has received funding from AstraZeneca for unrelated work. Roche, PhP, and AstraZeneca have had no part in this study, neither in the conception, design and execution of this study, nor in the preparation and contents of this manuscript. PHP is unrelated to the topics of advisory work performed to date.
Funding Statement
Dr. Sander W. van der Laan is funded through EU H2020 TO_AITION (grant number: 848146), and EU HORIZON MIRACLE (grant number: 101115381). Tim S. Peters and Dr. Sander W. van der Laan are funded through HealthHolland PPP Allowance 'Getting the Perfect Image'. Dr. Clint L. Miller is funded by National Institutes of Health (NIH) grants (R01HL148239, R01HL164577 and U01DK142283), Leducq Foundation network grant 'COMET' (24CVD02), Chan Zuckerberg Initiative Data Insights grant 'MetaPlaq', and American Heart Association Transformational Project Award (24TPA1300556). Dr. Clint L. Miller and Dr. Sander W. van der Laan are funded through EU HORIZON NextGen grant (101136962).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
The details of the IRB/oversight body that provided approval or exemption for the research described are given below:
Athero-Express Biobank Study (AE), an ongoing biobank study at the University Medical Centre Utrecht (Utrecht, The Netherlands) and the St. Antonius Hospital (Nieuwegein, The Netherlands)29. The medical ethical committees of the respective hospitals approved the AE which was registered under number 22/088. https://dataverse.nl/dataset.xhtml?persistentId=doi:10.34894/4IKE3T
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Footnotes
author affiliations have been updated
Data and code availability
Model: https://github.com/CirculatoryHealth/PHENOMICL
Downstream analyses: https://github.com/CirculatoryHealth/PHENOMICL_downstream
GWASToolKit: https://github.com/swvanderlaan/GWASToolKit
slideToolKit: https://github.com/swvanderlaan/slideToolKit
GWAS summary statistics: GWAS Catalog accession identifiers will be shared as soon as they are available.
DGEA results: https://doi.org/10.34894/ZODL42.
